Larimar Therapeutics, Inc. (LRMR) Tops Q2 EPS by 1c

Larimar Therapeutics, Inc. (NASDAQ: LRMR) reported Q2 EPS of ($0.19), $0.01 better than the analyst estimate of ($0.20).

For earnings history and earnings-related data on Larimar Therapeutics, Inc. (LRMR) click here.

You May Also Be Interested In

• Is the global equity rally broadening? UBS weighs in
• Ubiquiti (UI) Tops Q4 EPS by 25c, Beats on Revenue
• Hershey (HSY) PT Lowered to $206; RBC Capital: 'Struggling to See a Near Term Positive Inflection'